PubRank

Isabelle Dussault

Author PubWeight™ 13.41‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 STK33 kinase activity is nonessential in KRAS-dependent cancer cells. Cancer Res 2011 2.29
2 c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations. J Biol Chem 2007 1.34
3 Structure of the murine constitutive androstane receptor complexed to androstenol: a molecular basis for inverse agonism. Mol Cell 2004 1.11
4 Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines. Cancer Res 2010 1.08
5 Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo. Cancer Res 2008 0.97
6 Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase. J Med Chem 2008 0.97
7 Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors. Bioorg Med Chem Lett 2009 0.94
8 Design, synthesis, and biological evaluation of potent c-Met inhibitors. J Med Chem 2008 0.87
9 Structure-based design of novel class II c-Met inhibitors: 2. SAR and kinase selectivity profiles of the pyrazolone series. J Med Chem 2012 0.85
10 Structure-based design of novel class II c-Met inhibitors: 1. Identification of pyrazolone-based derivatives. J Med Chem 2012 0.83
11 Discovery of a potent, selective, and orally bioavailable c-Met inhibitor: 1-(2-hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458). J Med Chem 2008 0.81
12 Discovery of potent and selective 8-fluorotriazolopyridine c-Met inhibitors. J Med Chem 2015 0.77
13 Removal of the bile acid pool upregulates cholesterol 7alpha-hydroxylase by deactivating FXR in rabbits. J Lipid Res 2002 0.76
14 Correction to Discovery of Potent and Selective 8-Fluorotriazolopyridine c-Met Inhibitors. J Med Chem 2015 0.75
15 Discovery and optimization of a potent and selective triazolopyridinone series of c-Met inhibitors. Bioorg Med Chem Lett 2012 0.75